Trial on refinement of early stage non-small cell lung cancer. Adjuvant chemotherapy with pemetrexed and cisplatin versus vinorelbine and cisplatin: the TREAT protocol

Michael Kreuter, Johan Vansteenkiste, Frank Griesinger, Hans Hoffmann, Hendrik Dienemann, Paul De Leyn, Michael Thomas, Michael Kreuter, Johan Vansteenkiste, Frank Griesinger, Hans Hoffmann, Hendrik Dienemann, Paul De Leyn, Michael Thomas

Abstract

Background: Adjuvant chemotherapy has been proven to be beneficial for patients with early stage non-small cell lung cancer. However, toxicity and insufficient dose delivery have been critical issues with the chemotherapy used. Doublet regimens with pemetrexed, a multi-target folate inhibitor, and platin show clear activity in non-small cell lung cancer and are well tolerated with low toxicity rates and excellent delivery.

Methods/design: In this prospective, multi-center, open label randomized phase II study, patients with pathologically confirmed non-small cell lung cancer, stage IB, IIA, IIB, T3N1 will be randomized after complete tumor resection either to 4 cycles of the standard adjuvant vinorelbine and cisplatin regimen from the published phase III data, or to 4 cycles of pemetrexed 500 mg/m2 d1 and cisplatin 75 mg/m2 d1, q 3 weeks. Primary objective is to compare the clinical feasibility of these cisplatin doublets defined as non-occurrence of grade 4 neutropenia and/or thrombocytopenia > 7 days or bleeding, grade 3/4 febrile neutropenia and/or infection, grade 3/4 non-hematological toxicity, non-acceptance leading to premature withdrawal and no cancer or therapy related death. Secondary parameters are efficacy (time to relapse, overall survival) and drug delivery. Parameters of safety are hematologic and non-hematologic toxicity of both arms.

Discussion: The TREAT trial was designed to evaluate the clinical feasibility, i.e. rate of patients without dose limiting toxicities or premature treatment withdrawal or death of the combination of cisplatin and pemetrexed as well as the published phase III regimen of cisplatin and vinorelbine. Hypothesis of the study is that reduced toxicities might improve the feasibility of drug delivery, compliance and the convenience of treatment for the patient and perhaps survival.

Trial registration: ClinicalTrials.gov NCT00349089.

References

    1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007.
    1. Mountain C. Revisions in the international system for staging lung cancer. Chest. 1997;111:1710–1717.
    1. Non small Cell Lung Cancer Collaborative Group Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ. 1995;311:899–909.
    1. Tada H, Tsuchiya R, Ichinose Y, Koike T, Nishizawa N, Nagai K, Kato H. A randomized trial comparing adjuvant chemotherapy versus surgery alone for completely resected pN2 non-small cell lung cancer (JCOG9304) Lung Cancer. 2004;43:167–173. doi: 10.1016/j.lungcan.2003.08.028.
    1. Scagliotti GV, Fossati R, Torri V, Crino L, Giaccone G, Silvano G, Martelli M, Clerici M, Cognetti F, Tonato M. Adjuvant Lung Project Italy/European Organisation for Research Treatment of Cancer-Lung Cancer Cooperative Group Investigators. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J Natl Cancer Inst. 2003;95:1453–1461.
    1. Waller D, Peake MD, Stephens RJ, Gower NH, Milroy R, Parmar MK, Rudd RM, Spiro SG. Chemotherapy for patients with non-small cell lung cancer. The surgical setting of the Big Lung Trial. Eur J CardioThorax Surg. 2004;26:173–182. doi: 10.1016/j.ejcts.2004.03.041.
    1. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J. International Adjuvant Lung Cancer Trial Collaborative Group: Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350:351–360. doi: 10.1056/NEJMoa031644.
    1. Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, Cormier Y, Goss G, Inculet R, Vallieres E, Fry W, Bethune D, Ayoub J, Ding K, Seymour L, Graham B, Tsao MS, Gandara D, Kesler K, Demmy T, Shepherd F, National Cancer Institute of Canada Clinical Trials Group; National Cancer Institute of the United States Intergroup JBR.10 Trial Investigators Vinorelbine plus Cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005;352:2589–2597. doi: 10.1056/NEJMoa043623.
    1. Douillard J, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzáles-Larriba J, Grodzki T, Pereira J, Le Groumellec A, Lorusso V. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncology. 2006;7:719–727. doi: 10.1016/S1470-2045(06)70804-X.
    1. Pignon JP, Tribodet H, Sacgliotti GV, Douillard JY, Shepherd FA, Stephens RJ, Le Chevalier T. Lung adjuvant Cisplatin Evaluation (LACE) : A pooled analysis of fived randomized clinical trials including 4,584 patients. J Clin Oncol. 2006;24:366.
    1. Pisters KMW, Le Chevalier T. Adjuvant Chemotherapy in completely resected non-small cell lung cancer. J Clin Oncol. 2005;23:3270–3278. doi: 10.1200/JCO.2005.11.478.
    1. Alam N, Shepherd FA, Winton T, Graham B, Johnson D, Livingston R, Rigas J, Whitehead M, Ding K, Seymour L. Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer. An analysis of National Cancer Institute of Canada and Intergroup Trial JBR10 and review of the literature. Lung Cancer. 2005;47:385–394. doi: 10.1016/j.lungcan.2004.08.016.
    1. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar Manegold C, Paul S, Paoletti P, Einhorn L, Bunn PA., Jr Randomized phase III trial of Pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22:1589–1597. doi: 10.1200/JCO.2004.08.163.
    1. Scagliotti GV, Kortsik C, Dark GG, Price A, Manegold C, Rosell R, O'Brien M, Peterson PM, Castellano D, Selvaggi G, Novello S, Blatter J, Kayitalire L, Crino L, Paz-Ares L. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial. Clin Cancer Res. 2005;11:690–696. doi: 10.1158/1078-0432.CCR-05-9009.
    1. Clarke SJ, Abratt R, Goedhals L, Boyer MJ, Millward MJ, Ackland SP. Phase II trial of Pemetrexed disodium (PEMETREXED, LY231514) in chemotherapy-naive patients with advanced non-small-cell lung cancer. Ann Oncol. 2002;13:737–741. doi: 10.1093/annonc/mdf115.
    1. Rusthoven JJ, Eisenhauer E, Butts C, Gregg R, Dancey J, Fisher B, Iglesias J, for the National Cancer Institute of Canada Clinical Trials Group Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: a phase II study. J Clin Oncol. 1999;17:1194–1199.
    1. Manegold C, Gatzemeier U, von Pawel J, Pirker R, Malayeri R, Blatter J, Krejcy Kl. Front-line treatment of advanced non-small cell lung cancer with MTA and Cisplatin: a multicenter phase II trial. Ann Oncol. 2000;11:435–440. doi: 10.1023/A:1008336931378.
    1. Shepherd FA, Dancey J, Arnold A, Neville A, Rusthoven J, Johnson R, Fisher B, Eisenhauer E. Phase II study of Pemetrexed disodium, a multitargeted antifolate, and Cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma. A study of the National Cancer Institute of Canada Clinical Trials Group. Cancer. 2001;92:595–600. doi: 10.1002/1097-0142(20010801)92:3<595::AID-CNCR1359>;2-D.
    1. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P. Phase III study of Pemetrexed in combination with Cisplatin versus Cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636–2644. doi: 10.1200/JCO.2003.11.136.
    1. Simon R. Optimal two-stage designs for phase II clinical trials. Contr Clin Trials. 1989;10:1–10. doi: 10.1016/0197-2456(89)90015-9.
    1. British Thoracic Society (BTS) guidelines Guidelines on the selection of patients with lung cancer for surgery. Thorax. 2001;56:89–108. doi: 10.1136/thorax.56.2.89.
    1. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, Demetri G, Desch CE, Pizzo PA, Schiffer CA, Schwartzberg L, Somerfield MR, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Wolff AC. update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24:3187–3205. doi: 10.1200/JCO.2006.06.4451.
    1. Maschmeyer G, Böhme A, Buchheidt D, Cornely OA, Fricke HJ, Karthaus M, Lehrnbecher T, Link H, Shah PM, Wilhelm M. Diagnostik und Therapie von Infektionen bei Patienten in der Hämatologie und Onkologie, Leitlinien der Sektion Infektionen in der Hämatologie/Onkologie der Paul-Ehrlich-Gesellschaft e.V. Chemotherapie Journal. 2004;13:134–141. doi: 10.1159/000076567.
    1. Hoffmann H, Dienemann H. Lymphknotendissektion bei Bronchialkarzinom. Zentralbl Chir. 1999;124:115–119.
    1. Junker K. Histopathologic Evaluation of mediastinal lymph nodes in lung cancer. Lung Cancer. 2004:S79–83. doi: 10.1016/j.lungcan.2004.07.988.
    1. Wittekind C, Compton CC, Greene FL, Sobin LH. TNM Residual Tumor Classification Revisited. Cancer. 2002;94:2511–2516. doi: 10.1002/cncr.10492.
    1. National Cancer Institute (NCI) Cancer therapy evaluation program common terminology criteria for adverse events, Version 3.0. 2003.
    1. Ethikkommission der Med. Fakultät Heidelberg

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir